Image courtesy of St. Jude Medical
October 28, 2015 — St. Jude Medical Inc. announced the company has received CE Mark approval for the HeartMate 3 Left Ventricular Assist System (LVAS). HeartMate 3 is a cardiac support option for advanced heart failure patients who are awaiting transplantation, are not candidates for heart transplantation or are in myocardial recovery.
“The advanced heart failure medical community has eagerly anticipated the expected clinical improvements with the HeartMate 3 system and looks forward to its broad adoption throughout Europe,” said Prof. Friedhelm Beyersdorf, medical director, Department of Cardiovascular Surgery, Heart Center Freiburg University.
The HeartMate 3 system is the first commercially approved centrifugal-flow left ventricular assist device (LVAD) utilizing Full MagLev (fully magnetically-levitated) technology, which allows the device’s rotor to be “suspended” by magnetic forces. This design aims to reduce trauma to blood passing through the pump and improve outcomes for patients.
The device is implanted above the diaphragm immediately next to the native heart and is attached to the aorta, leaving natural circulation in place while providing all of the energy necessary to propel blood throughout the body.
CE Mark approval for the system was based on data from the HeartMate 3 CE Mark clinical trial, which met its primary endpoint and demonstrated a 92 percent six-month survival rate — the best six-month survival rate to date to be documented in an LVAD CE Mark clinical study.
St. Jude Medical expects a limited market release across Europe to begin immediately, with additional market releases taking place throughout 2016.
Unlike artificial hearts, LVADs don’t replace the heart. Instead, the small implantable devices supplement the pumping function of the heart in patients whose hearts are too weak to pump blood adequately on their own. LVADs can benefit patients either awaiting transplant, known as bridge to transplant therapy, or can be used as a “destination therapy” for heart failure patients who need years of cardiac support but who are not candidates for transplantation.
The design of the HeartMate 3 LVAD includes large, consistent blood flow gaps over a wide range of device operation levels, designed to reduce blood trauma. The artificial pulse technology is designed to further reduce adverse patient events including combatting the formation of thrombus in the device.
The HeartMate 3 CE Mark clinical trial, which concluded in November 2014, enrolled 50 patients at 10 hospitals in six countries outside the United States. Enrollment included both bridge-to-transplant and destination therapy patients in New York Hospital Association (NYHA) Class IIIb or IV heart failure. The study met its primary endpoint by demonstrating a six-month survival rate of 92 percent with the HeartMate 3 LVAS, as well as overall adverse event rates that were either lower or consistent with expectations for severely ill and complex patients requiring LVAD support. In the United States, the HeartMate 3 system is in an ongoing investigational device exemption (IDE) trial. The MOMENTUM 3 IDE trial, the largest of its kind, remains ongoing and will enroll more than 1,000 patients.
For more information: www.sjm.com
